Sanofi

Elenestinib is an experimental small-molecule drug from Blueprint Medicines in phase 3 trials for systemic mastocytosis, with its target not yet stated publicly.

ADG126 is an experimental monoclonal antibody from Adagene in phase 2 trials for hepatocellular carcinoma, aimed at CTLA-4.

Buserelin is one of the original GnRH agonists, approved in Europe and Canada in the 1980s for advanced prostate cancer and also used in endometriosis and fertility treatment; it is not sold in the United States.

Fludarabine is a chemotherapy infusion for chronic lymphocytic leukaemia. It anchored the FCR regimen that was the first to give long remissions, and today it is used above all to prepare patients for CAR-T cells and transplants.

An alpha-particle version of neuroendocrine radioligand therapy that produced responses in over half of patients who had never had PRRT, with FDA Breakthrough designation.

Alemtuzumab (Campath) is an antibody that wipes out lymphocytes carrying the CD52 marker. It is approved for chronic lymphocytic leukaemia and is supplied in the US through a restricted distribution programme.

Avapritinib is the first drug for GIST driven by the PDGFRA D842V mutation, which resists every other kinase inhibitor; it is also approved for systemic mastocytosis.

Belumosudil is a pill for chronic graft-versus-host disease, the long-term immune complication of donor stem-cell transplants used to cure blood cancers.

A second taxane that works after docetaxel and beat a second hormone pill head-to-head (CARD).

Clofarabine (Clolar) is an infusion for children and young adults whose acute lymphoblastic leukaemia has come back after at least two other treatments.

The first chemotherapy to extend life in prostate cancer (2004), now part of triplet therapy at first metastatic diagnosis.

Billed as the first PARP inhibitor for triple-negative breast cancer, it failed its phase 3 in 2011. It turned out not to inhibit PARP at all.

Isatuximab is Sanofi's CD38 antibody, approved in frontline transplant-ineligible myeloma (IMROZ) and, from July 2026, as an under-the-skin injection.

The platinum drug that works in bowel cancer where cisplatin does not, the 'OX' in FOLFOX and CAPOX; its cost is nerve damage in hands and feet.

Plerixafor (Mozobil) is an injection given with G-CSF to flush stem cells out of the bone marrow into the blood so that enough can be collected for an autologous transplant in myeloma or lymphoma.

Rasburicase (Elitek) is an enzyme infusion that rapidly dissolves the uric acid released when large numbers of leukaemia or lymphoma cells die at the start of treatment, protecting the kidneys from tumour lysis syndrome.

Thyrogen is an injected version of thyroid-stimulating hormone that lets people with thyroid cancer have radioiodine treatment and follow-up blood tests without stopping their thyroid hormone tablets and suffering weeks of hypothyroidism.

Tusamitamab ravtansine was Sanofi's ADC against the classic CEA tumour marker, stopped for futility in lung cancer in 2023.

Vandetanib was the first drug approved for medullary thyroid cancer (2011), now largely replaced by RET-selective selpercatinib.

Ziv-aflibercept (Zaltrap) is a decoy receptor that soaks up the blood-vessel growth signal VEGF. It is added to the FOLFIRI chemotherapy combination for bowel cancer that has spread and progressed after oxaliplatin.